VTE, from investigation to treatment

Dr Pavel Chudakou Consultant Haematologist United Lincolnshire Hospital NHS Trust

Green text to be removed on use:

These intro slides (slides 1 & 2 only) may be changed post certification

This promotional [meeting/presentation] is organised and funded by Pfizer Ltd

on behalf of the Bristol-Myers Squibb - Pfizer Alliance



H Bristol Myers Squibb[®]



Prescribing Information for

Eliquis (apixaban)


is available at this meeting or attached to the Joining Instructions if joining via WebEx.


Adverse events should be reported. Reporting forms and information can be found at: UK - <u>www.mhra.gov.uk/yellowcard</u> or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Bristol-Myers Squibb via medical.information@bms.com or 0800 731 1736 (UK)



Introduction to VTE and its pathology

- Incidence of VTE is approximately one per 1,000 people annually¹
- VTE comprises DVT and PE: one-third of cases are PEs; two-thirds are DVTs¹
- The 30-day mortality risk has been estimated as 3% for DVT and 31% for PE*²






virchow's triad summarises the factors that contribute to the development of VTE; **venous stasis** is thought to play the biggest role⁴

*Based on a retrospective analysis of 128,223 patients in the Danish National Registry of Patients who had a first-time hospital discharge diagnosis of VTE (74,157 had DVT, 54,066 had PE) (January 1980–December 2011).²

DVT: deep vein thrombosis; PE: pulmonary embolism; VTE: venous thromboembolism.

 Stone J, et al. Cardiovasc Design Ther 2017;9(Suppl. 3):S276–S284; 2. Søgaard S, et al. Circulation 2014;130:829–836;
 Blood clot diagram. Wikimedia Commons. Available at: https://commons.wikimedia.org/wiki/File:Blood_clot_diagram.png. Last accessed: August 2020; 4. Behravesh S, et al. Thrombosis 2017;2017:3039713.

Examples of risk factors for VTE^{1,2}



*Heart disease, metabolic, endocrine or respiratory pathologies, acute infectious diseases and inflammatory conditions. BMI: body mass index.

> NICE clinical guideline (CG92). Venous thromboembolism: reducing the risk for patients in hospital. January 2010. Available at: https://www.nice.org.uk/guidance/cg92/resources; 2. Bahl V, et al. Ann Surg 2009;251:344-350.

Clinical presentation of DVT: Signs and symptoms^{1,2}





If a patient presents with signs or symptoms of DVT, carry out an assessment of their general medical history and a physical examination to exclude other causes³

		•	
P		15	
	_	11	
1=	_		
-	_		
\sim	_	/	

If DVT is suspected, use the two-level DVT Wells score to estimate the clinical probability of DVT^3

1. Moll S, et al. Arterioscler Thromb Vasc Biol 2008;28:373–379; 2. Pai M, et al. Available at: http://www.uptodate.com/contents/deep-vein-throm bosis-dvt-beyond-thebasics. Last accessed: August 2020; 3. National Institute for Health and Care Excellence. NICE Guidance NG158. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. March 2020. Available at: https://www.nice.org.uk/guidance/ng158/. Last accessed: August 2020.

Two-level DVT Wells score to estimate probability of D'


of DVT	
Two-level Wells DVT risk score ¹	
Clinical feature	Points
Active cancer (on treatment/treated in the past 6 months/palliative)	1
Paralysis, paresis or recent plaster immobilisation of the lower extremities	1
Recently bedridden for 3 days or more, or major surgery within 12 weeks requiring general or regional anaesthesia	1
Localised tenderness along the distribution of the deep venous system	1
Entire leg swollen	1
Calf swelling at least 3 cm larger than asymptomatic side	1
Pitting oedema confined to the symptomatic leg	1
Collateral superficial veins (non-varicose)	1
Previously documented DVT	1
An alternative diagnosis is at least as likely as DVT	-2
Clinical probability	
DVT likely	≥2 points

DVT unlikely

1. National Institute for Health and Care Excellence. NICE Guidance NG158. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. March 2020. Available at: https://www.nice.org.uk/guidance/ng158/. Last accessed: August 2020.

≤1 point

Suspected DVT: diagnosis and initial management



In the AMPLIFY trial, apixaban was given to patients with a confirmed DVT/PE. The use of an appropriate anticoagulant for patients with a suspected DVT/PE whilst awaiting confirmatory diagnostic tests is a clinical decision based on individual patient assessment

*Laboratory or point-of-care test. Consider age-adjusted threshold for people over 50.

[†]Note that only one D-dimer test is needed during diagnosis.


⁺Measure baseline blood count, renal and hepatic function, PT and APTT but start anticoagulation before results available and review within 24 hours.

 ${}^{\$}$ If possible, choose an anticoagulant that can be continued if DVT confirmed.

APTT: activated partial thromboplastin time; LMWH: low-molecular-weight heparin; PT: prothrombin time.

 National Institute for Health and Care Excellence. NICE Guidance NG158. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. March 2020. Available at: https://www.nice.org.uk/guidance/ng158/resources/visual-summary-pdf-8709091453.
 Last accessed: August 2020.

Clinical presentation of PE: Signs and symptoms^{1,2}





If a patient presents with signs or symptoms of a PE, carry out an assessment of their general medical history and a physical examination to exclude other causes³



For suspected PE, refer for a chest X-ray to exclude other causes³



If PE is suspected, use the two-level PE Wells score to estimate the clinical probability of PE^3

1. Taylor Thompson B, et al. Available at: http://www.uptodate.com/contents/pulmonary-embolism-beyond-the-basics. Last accessed: August 2020; 2. Sekhri V, et al. Arch Med Sci 2012;8:957–969; 3. National Institute for Health and Care Excellence. NICE Guidance NG158. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. March 2020. Available at: https://www.nice.org.uk/guidance/ng158/. Last accessed: August 2020; 2. Sekhri V, et al. Arch Med

Two-level PE Wells score to estimate probability of PE

Two-level Wells PE risk score ¹	
Clinical feature	Points
Clinical signs and symptoms of DVT (minimum of leg swelling and pain with palpation of the deep veins)	3
An alternative diagnosis is less likely than PE	3
Heart rate >100 beats per minute	1.5
Immobilisation for more than 3 days or surgery in the previous 4 weeks	1.5
Previous DVT/PE	1.5
Haemoptysis	1
Malignancy (on treatment, treated in the last 6 months, or palliative)	1
Clinical probability simplified scores	
PE likely	>4 points
PE unlikely	≤4 point

1. National Institute for Health and Care Excellence. NICE Guidance NG158. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. March 2020. Available at: https://www.nice.org.uk/guidance/ng158/. Last accessed: August 2020.

A REAL

NICE guidance on pulmonary embolism rule-out criteria (PERC)


If clinical suspicion of PE is low,* consider using PERC to help determine whether any further investigations for PE are needed¹

PERC criteria	Recurrence score	PERC score	Risk of PE
Age ≥50 years	+1		No need for further
HR ≥100	+1	0	work-up as <2% chance of PE
O2 saturation on room air <95%	+1		
Unilateral leg swelling	+1	≥1	PERC cannot be used to rule-out a PE
Haemoptysis	+1		Adapted from MDCalc. ²
Recent surgery or trauma ⁺	+1		
Prior DVT or PE	+1		
Hormone use [‡]	+1		

*The clinician estimates the likelihood of PE to be less than 15% based on the overall clinical impression and other diagnoses are feasible;^{1†}Surgery or trauma ≤4 weeks ago requiring treatment with general anaesthesia; [‡]Oral contraceptives, hormone replacement or oestrogenic hormones use in male or female patients.

1. National Institute for Health and Care Excellence. NICE Guidance NG158. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. March 2020. Available at: https://www.nice.org.uk/guidance/ng158/. Last accessed: August 2020; 2. MDCalc. PERC Rule for Pulmonary Embolism. Available at: https://www.mdcalc.com/perc-rule-pulmonary-embolism. Last accessed: August 2020.

Suspected PE: diagnosis and initial management



Consider outpatient treatment for low-risk PE

In the AMPLIFY trial, apixaban was given to patients with a confirmed DVT/PE. The use of an appropriate anticoagulant for patients with a suspected DVT/PE whilst awaiting confirmatory diagnostic tests is a clinical decision based on individual patient assessment

*CT pulmonary angiogram. Assess suitability of V/A SPECT or V/Q planar scan for allergy, severe renal impaiment (CrCl <30mL/min estimated using the Cockcroft and Gault formula) or high irradiation risk.

⁺Laboratory or point-of-care test. Consider age-adjusted threshold for people over 50.

*Measure baseline blood count, renal and hepatic function, PT and APTT but start anticoagulation before results are available and review within 24 hours.

[§]If possible, choose an anticoagulant that can be continued if PE is confirmed.

 National Institute for Health and Care Excellence. NICE Guidance NG158. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. March 2020. Available at: https://www.nice.org.uk/guidance/ng158/resources/visual-summary-pdf-8709091453. Last accessed: August 2020.


D-dimer and NICE guidance on D-dimer testing

When offering D-dimer testing for suspected DVT or PE, consider a **point-of-care test** if laboratory facilities are not immediately available.

If using a point-of-care D-dimer test, choose a fully **quantitative** test

When using a point-of-care or laboratory Ddimer test, consider **an age-adjusted D-dimer test threshold for people aged over 50**

D-dimer is formed from the breakdown of fibrin²



 National Institute for Health and Care Excellence. NICE Guidance NG158. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. March 2020. Available at: https://www.nice.org.uk/guidance/ng158/. Last accessed: August 2020; 2. Wikimedia Commons. D-dimer diagram. Available at: https://commons.wikimedia.org/wiki/File:D-dimer.png. Last accessed August 2020.

NICE guidance on initiating anticoagulation for confirmed DVT or PE¹

For confirmed proximal DVT or PE, offer anticoagulation for at least 3 months¹

- ► Carry out baseline blood tests, including:¹
 - Full blood count
 - Tests of renal and hepatic function
 - PT and APTT
- Do not wait for the results of blood tests before starting anticoagulation¹
- Review and, if necessary, act on the results of baseline blood tests within 24 hours of starting interim therapeutic anticoagulation



When offering anticoagulation, take into account comorbidities, contraindications and the person's preferences¹

In the AMPLIFY trial, apixaban was given to patients with a confirmed DVT/PE. The use of an appropriate anticoagulant for patients with a suspected DVT/PE whilst awaiting confirmatory diagnostic tests is a clinical decision based on individual patient assessment

APTT: activated partial thromboplastin time; PT: prothrombin time.

 National Institute for Health and Care Excellence. NICE Guidance NG158. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. Available at: https://www.nice.org.uk/guidance/ng158/. Last accessed: August 2020;
 Image source: Wikimedia commons. Available at: https://commons.wikimedia.org/wiki/File:Blooddraw.jpg. Last accessed: August 2020.

NICE guidance on treating a confirmed VTE in patients without renal impairment (CrCl ≥50 mL/min)¹

Confirmed DVT or PE

PE with haemodynamic instability

Offer continuous UFH infusion and consider thrombolytic therapy

Do not offer elastic graduated compression stockings to prevent PTS or VTE recurrence after a DVT[#]

Confirmed proximal DVT or PE

When offering anticoagulation, take into account comorbidities, contraindications and the person's preferences

For patients who **do not** have CrCl <15mL/min, active cancer, triple positive APS, extreme body weight <50kg or >120kg, or a PE with haemodynamic instability:^{*†‡§}

Offer either apixaban or rivaroxaban to people with a confirmed proximal DVT or PE

If neither a pixaban nor rivaroxaban is suitable offer one of the following:

- LMWH for ≥5 days followed by dabigatran
- LMWH for ≥5 days followed by edoxaban
- LMWH concurrently with a VKA[®]

Offer anticoagulation treatment for ≥3 months for people with confirmed proximal DVT or PE

Symptomatic iliofemoral DVT

Consider catheter-directed thrombolytic therapy for patients with symptomatic iliofemoral DVT who have all of:

- Symptoms of <14 days' duration
- Good functional status
- A life expectancy of ≥1 year
- A low risk of bleeding

*Apixaban, rivaroxaban and edoxaban are not recommended in patients with a CrCl of <15 mL/min, and patients undergoing dialysis. Apixaban and rivaroxaban should also be used with caution in patients with severe renal impairment (CrCl 15–29 mL/min). Dabigatran is contraindicated in patients with a CrCl of <30mL/min. [†]The efficacy and safety outcomes of apixaban in the treatment of DVT / PE and prevention of recurrent DVT / PE in patients with active cancer have not been established.

All prescribing must be in accordance with the appropriate SmPC

^{*}The DOACs, including apixaban, should not be used in patients with a history of thrombosis who are diagnosed with antiphosphdipid syndrome.

[§]See the NICE NG158 guidelines for recommendations in these patient groups.

¶LMWH should be given concurrently with a VKA for at least 5 days, or until the INR is at least 2.0 in 2 consecutive readings, followed by a VKA on its own.

#This recommendation does not cover the use of elastic compression stockings for the management of leg symptoms after DVT.

APS: antiphospholipid syndrome: LMWH: low molecular weight heparin: PTS: post-thrombotic syndrome: VKA: vitamin K antaaonist.

1. National Institute for Health and Care Excellence. NICE Guidance NG158. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. March 2020. Available at: https://www.nice.org.uk/guidance/ng158/. Last accessed: August 2020.

NICE guidance on anticoagulation in patients with VTE and renal impairment or established renal failure*

Established renal failure	Severe renal impairment	Moderate renal
(CrCl <15mL/min)	(CrCl 15–29 mL/min)	impairment
 Offer one of the following: LMWH UFH LMWH/VKA⁺ UFH/VKA⁺ 	 Offer one of the following: Apixaban Rivaroxaban LMWH for ≥5 days followed by edoxaban LMWH/VKA[†] UFH/VKA[†] 	 Offer one of the following: Apixaban Rivaroxaban LMWH for ≥5 days followed by: Edoxaban Dabigatran LMWH/VKA[†] UFH/VKA[†]
[†] LMWH or UFH should be given concurrently with	[†] LMWH or UFH should be given concurrently with	[†] LMWH or UFH should be given concurrently with
a VKA for ≥5 days or until the INR is ≥2.0 in 2	a VKA for ≥5 days or until the INR is ≥2.0 in 2	a VKA for ≥5 days or until the INR is ≥2.0 in 2
consecutive readings, followed by a VKA on its	consecutive readings, followed by a VKA on its	consecutive readings, followed by a VKA on its
own	own	own

Apixaban and rivaroxaban should be used with caution in patients with severe renal impairment (CrCl 15–29mL/min) for the treatment of DVT and PE. Apixaban, rivaroxaban and edoxaban are not recommended in patients with a CrCl of <15 mL/min, and patients undergoing dialysis. Dabigatran is contraindicated in patients with a CrCl of <30mL/min.

All prescribing must be in accordance with the appropriate SmPC.

*When giving anticoagulation treatment to people with renal impairment or established renal failure, note the cautions and requirements for dose adjustment and monitoring in the medicine's SmPC and follow locally agreed protocols or advice from a specialist or multidisciplinary team. CrCl: creatinine clearance; INR: international normalised ratio; LMWH: low molecular weight heparin; UFH: unfractionated heparin; VKA: vitamin K antagonist.

> National Institute for Health and Care Excellence. NICE Guidance NG158. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. March 2020. Available at: https://www.nice.org.uk/guidance/ng158/. Last accessed: August 2020.

NICE guidance on anticoagulation in patients with VTE at extremes of weight*


Consider anticoagulation with regular monitoring of therapeutic levels for people with confirmed proximal DVT or PE who weigh <50 kg or > 120 kg to ensure effective anticoagulation*



*Note the cautions and requirements for dose adjustment and monitoring in the appropriate SmPCs, and follow locally agreed protocols or advice from a specialist or multidisciplinary team. See the respective SmPC for specific information on each DOAC.

> National Institute for Health and Care Excellence. NICE Guidance NG158. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. Available at: https://www.nice.org.uk/guidance/ng158/. Last accessed: August 2020.

Phases of pharmacological treatment in VTE



*Heparin, LMWH or fondaparinux; [†]As per their SmPCs, apixaban and rivaroxaban do not require initial treatment with parenteral anticoagulation.^{3,4} [‡]Parenteral anticoagulant should be taken for ≥5 days before dabigatran or edoxaban.^{5,6} [§]Includes I MWH and DOACs.

All prescribing must be in accordance with the appropriate SmPC.

A/C: anticoagulation; DOAC: direct oral anticoagulant; LMWH: low-molecular weight heparin; SmPC, summary of product characteristics.

1.Kearon C, et al. *Chest* 2012;141(Suppl.):e419s–e494s; 2. Kearon C. *J Thromb Haemost* 2012;10:507–511;
 3. Apixaban SmPC. Available at: http://www.medicines.org.uk ; 4. Rivaroxaban SmPC. Available at: http://www.medicines.org.uk ;
 5. Dabigatran SmPC. Available at: http://www.medicines.org.uk ; 6. Edoxaban SmPC. Available at: http://www.medicines.org.uk ;

Design of DOAC trials in acute VTE treatment

DOAC	Trial	Number of patients	Design	Parenteral required before DOAC?	DOAC dosing	Comparator	Treatment length (months)	Follow-up period	Key inclusion criteria				
Dabigatran	RE-COVER ¹	2,564 DVT: 1,749 PE: 786	Double-blind	LMWH/UFH for at least 5	Dabigatran	LMWH or UFH bridge	6	30 days after study	PErequiring				
Dabigatian	RE-COVER II ²	2,589 DVT: 1,750 PE: 816		days					150 mg BD	to warfarin	0	completion	treatment for at least 6 months
		8,240		Enoxaparin or		Enoxaparin or UFH		For duration	DVT without PE				
Edoxaban	Hokusai-VTE ³	DVI: 4,921 PE: 3,319	Double-blind	ind UFH for at least 5 days	Edoxaban 60 mg OD ⁺	bridge to warfarin	3–12	of treatment	PE with or without DVT				
	EINSTEIN-DVT ⁴	DVT: 3,449	Open-label No				No	No	Rivaroxaban 15 mg BD for	Enoxaparin	3,6	Forduration	DVT without PE
Rivaroxaban	EINSTEIN-PE ⁵	PE: 4,832		No	No	No			No	21 days, then 20 mg OD	bridgeto VKA	or 12*	of treatment
Apixaban	AMPLIFY ⁶	5,395 DVT: 3,532 PE: 1,836	Double-blind	No	Apixaban 10 mg BD for 7 days, then 5 mg BD	Enoxaparin bridgeto warfarin	6	study	DVT/PE requiring treatment for at least 6 months				

Please refer to individual study publications and product SmPCs for further information

*Duration of treatment was determined by the treating physician before randomisation. Most patients received 6 or 12 months of therapy; [†]Patients with body weight ≤60 kg or a CrCl of 30–50 mL/min, and patients receiving concomitant treatment with potent P-gp inhibitors were treated with edoxaban 30 mg OD.

BD: twice daily; CrCl: creatinine clearance; OD: once daily; P-gp: P-glycoprotein; UFH: unfractionated heparin.

Schulman S, et al. N Engl J Med 2009;361:2342–2352; 2. Schulman S, et al. Circulation 2014;129:764–772;
 Hokusai-VTE Investigators. N Engl J Med 2013;369:1406–1415 4. EINSTEIN Investigators. N Engl J Med 2010;363:2499–2510;
 EINSTEIN-PE Investigators. N Engl J Med 2012;366:1287–1297; 6. Agnelli G, et al. N Engl J Med 2013;369:799–808.

Meta-analysis: Pooled data comparison of the efficacy and safety of the DOACs versus VKAs in acute VTE¹

Recurrent VTE/VTE-related death

	DOACs		War	farin		Risk ratio (95% CI)
Study	n	Total	n	Total		
AMPLIFY	59	2,609	71	2,635	0.84 (0.60–1.18)	
RE-COVER	30	1,274	27	1,265	1.10 (0.66–1.84)	
RE-COVER II	30	1,279	28	1,289	1.08 (0.65–1.80)	
EINSTEIN-DVT	36	1,731	51	1,718	0.70 (0.46–1.07)	
EINSTEIN-PE	50	2,419	44	2,413	1.13 (0.76–1.69)	
Hokusai-VTE*	66	4,118	80	4,122	0.83 (0.60–1.14)	
Combined (random effects)	271	13,430	301	13,442	0.90 (0.77–1.06)	
Heterogeneity: I ² =0%; <i>P</i> =0.53					0	DOAC better 1.0 VKA better 2.

Major bleeding

	DOACs		Warfarin			Risk ratio (95% CI)		
Study	n	Total	n	Total				
AMPLIFY	15	2,676	49	2,689	0.31 (0.17–0.55)			
RE-COVER	22	1,273	29	1,266	0.75 (0.44–1.31)			
RE-COVER II	15	1,280	22	1,288	0.69 (0.36–1.32)			
EINSTEIN-DVT	14	1,718	20	1,711	0.70 (0.35–1.38)	e		
EINSTEIN-PE	26	2,412	52	2,405	0.50 (0.31–0.80)			
Hokusai-VTE	56	4,118	66	4,122	0.85 (0.60–1.21)			
Combined (random effects)	148	13,477	238	13,481	0.61 (0.45–0.83)	8		
Heterogeneity: I ² =51%; P=0.07	Heterogeneity: 1 ² =51%; P=0.07							
					0	.1 • 1	.0 2	

There are no head-to-head randomised clinical trials comparing DOACs Comparisons cannot be made between individual DOACs based on these data

*For Hokusai-VTE, the event data is for the on-treatment period only. CI: confidence interval. Adapted from van Es et al. 2014.¹


VKA better

DOAC better

AMPLIFY: Apixaban was non-inferior to warfarin in the treatment of acute VTE and had a significantly lower incidence of major bleeding

Apixaban vs enoxaparin/warfarin

Apixaban was non-inferior to warfarin for first VTE recurrence/VTE-related death and had a lower risk of major bleeding for the treatment of acute VTE¹




*All efficacy analyses included data for patients in the ITT population for whom the outcome status at 6 months was documented; [†]All safety analyses included data obtained from patients during study treatment, defined as the time from administration of the first dose until 48 hours after the last dose was administered.

EINSTEIN-DVT: Rivaroxaban was non-inferior to enoxaparin/VKA in the treatment of acute DVT, with no significant difference in major or CRNM bleeding

Rivaroxaban vs enoxaparin/VKA


Rivaroxaban was non-inferior to enoxaparin/VKA in the treatment of acute DVT with no significant difference in rates of major or CRNM bleeding¹



*The primary efficacy analysis was performed on an ITT basis; [†]Recurrent VTE was defined as the composite of DVT or non-fatal or fatal PE; [‡]The non-inferiority margin was 2.0; [¶]The safety analyses included all patients who received the assigned study drug. EINSTEIN-PE: Rivaroxaban was non-inferior to enoxaparin/VKA in the treatment of acute PE, with no significant difference in major or CRNM bleeding

Rivaroxaban vs enoxaparin/VKA

Rivaroxaban was non-inferior to enoxaparin/VKA in the treatment of acute PE with no significant difference in rates of major or CRNM bleeding¹




*The primary analysis was performed on an ITT basis; [†]Recurrent VTE was defined as the composite of DVT or non-fatal or fatal PE; [‡]The non-inferiority margin was 2.0; [¶]The population for the safety analysis included all patients who received at least one dose of a study drug. The features of DOACs compared with VKAs that may benefit appropriate patients with a VTE^{1–5}

- Reach peak concentration quickly
- No significant food interactions
- Less drug/drug interactions
- No requirement for routine coagulation monitoring
- Practical concerns:
 - Dosing is dependent on the specific DOAC¹⁻⁴
 - Suboptimal adherence can impair treatment outcomes (due to the short half-life of the DOACs¹⁻⁵)



Apixaban SmPC. Available at: www.medicines.org.uk; 2. Dabigatran SmPC. Available at: www.medicines.org.uk;
 Rivaroxaban SmPC. Available at: www.medicines.org.uk; 4. Edoxaban SmPC. Available at: www.medicines.org.uk;
 S. Mekaj YH, et al. *Ther Clin Res Manag* 2015;11:967–977.

Phases of pharmacological treatment in VTE




*Heparin, LMWH or fondaparinux; [†]As per their SmPCs, apixaban and rivaroxaban do not require initial treatment with parenteral anticoagulation.^{3,4} [‡]Parenteral anticoagulant should be taken for ≥5 days before dabigatran or edoxaban.^{5,6} [§]Includes I MWH and DOACs.

All prescribing must be in accordance with the appropriate SmPC.

A/C: anticoagulation; DOAC: direct oral anticoagulant; LMWH: low-molecular weight heparin; SmPC, summary of product characteristics.

1.Kearon C, et al. Chest 2012;141(Suppl.):e419s-e494s; 2. Kearon C. J Thromb Haemost 2012;10:507-511;
 3. Apixaban SmPC. Available at: http://www.medicines.org.uk ; 4. Rivaroxaban SmPC. Available at: http://www.medicines.org.uk ; 5. Dabigatran SmPC. Available at: http://www.medicines.org.uk ; 6. Edoxaban SmPC. Available at: http://www.medicines.org.uk .

Over half of VTEs are unprovoked and long-term anticoagulation should be considered in these patients




*E.g. surgery, trauma, significant immobility (bedbound, unable to walk unaided or likely to spend a substantial proportion of the day in bed or in a chair), pregnancy or puerperium; ⁺Oral contraceptive or hormone replacement therapy.

 National Institute for Health and Care Excellence. Economic modelling report for pharmacological treatment in people with confirmed deep vein thrombosis and/or pulmonary embolism. March 2020. Available at: https://www.nice.org.uk/guidance/ng158/evidence/g-economicmodelling-report-on-pharmacological-treatment-pdf-8710588340. Last accessed: August 2020; 2. National Institute for Health and Gare Excellence. NICE Guidance NG158. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. March 2020. Available at: https://www.nice.org.uk/guidance/ng158/. Last accessed: August 2020;


Stopping anticoagulation increases recurrence risk in unprovoked VTE and VTE with non-surgical transient risk factors

Cumulative proportions of recurrent thrombosis after cessation of anticoagulant therapy following first-episode VTE (n=558)¹



Crude incidences of recurrent VTE according to baseline risk factor profiles in the placebo arm of EINSTEIN-Extension

This study looked at the EINSTEIN Extension and EINSTEIN CHOICE randomized, double-blind studies of the efficacy and safety of rivaroxaban (20 mg OD) with placebo and rivaroxaban (20 mg OD) or 10 mg OD) with aspirin (100 mg), respectively, for extended treatment of VTE. Result s shown are of recurrent VTE rates for the placebo arm of EINSTEIN Extension. This was not a pre-specified endpoint. No clinical conclusions can be made from these results



*The efficacy and safety outcomes of apixaban in the treatment of DVT / PE and prevention of recurrent DVT / PE in patients with active cancer have not been established. [†]Apixaban, rivaroxaban and edoxaban are not recommended in patients with a CrCl of <15 mL/min, and patients undergoing dialysis. Apixaban and rivaroxaban should also be used with caution in patients with severe renal impairment (CrCl 15 –29 mL/min). Dabigatran is contraindicated in patients with a CrCl of <30mL/min. [‡]The DOACs, including apixaban, should not be used in patients with a history of thrombosis who are diagnosed with antiphosphdipid syndrome. [§]Avoid use of apixaban during pregnancy and breast feeding. Rivaroxaban is contraindicated during pregnancy and breast feeding.

[‡]Known thrombophilia includes deficiency of antithrombin, protein C, or protein S, factor V Leiden or prothrombin gene mutation. APS: antiphospholipid syndrome; BMI: body mass index; CHF: congestive heart failure. Long-term anticoagulation should be considered in unprovoked VTE because of the high risk of recurrence¹

NICE guidance for long-term anticoagulation in unprovoked DVT or PE For people who had an unprovoked DVT or PE, consider continuing anticoagulation treatment beyond 3 months

Base the decision on the balance between the person's risk of VTE recurrence and their risk of bleeding

Discuss the risks and benefits with the person, and take their preferences into account

Explain to people with unprovoked DVT or PE and a low bleeding risk that the benefits of continuing anticoagulation treatment are likely to outweigh the risks

 National Institute for Health and Care Excellence. NICE Guidance NG158. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. March 2020. Available at: https://www.nice.org.uk/guidance/ng158/. Last accessed: August 2020.

The HAS-BLED score can be used to assess the risk of major bleeding in people on anticoagulation for unprovoked VTE¹

Letter	Clinical characteristic	Points awarded
н	Hypertension	1
А	Abnormal renal* and liver [†] function (1 point each)	1 or 2
S	Stroke	1
В	Bleeding [‡]	1
L	Labile INRs	1
E	Elderly (e.g. age >65 years)	1
D	Drugs or alcohol (1 point each)	1 or 2
HAS-BLED Score	Cumulative incidence for major bleeding	
3	5.3% (4.9–5.6)	High risk for major
≥4	8.0 (7.3–8.7)	bleeding


Adapted from CammAJ et al, 2010, and Brown JD, et al, 2018^{2,3}

Discuss stopping anticoagulation if the HAS-BLED score is ≥4 and cannot be modified¹

*Abnormal renal function is the defined as the presence of chronic dialysis, renal transplantation, or a serum creatinine level of \geq 200 µmol/L; [†]Abnormal liver function is defined as chronic hepatic disease (e.g. cirrhosis), or biochemical evidence of significant hepatic derangement (e.g. bilirubin >2 x upper limit of normal, in association with aspartate aminotransferase/alanine aminotransferase/alkaline phosphatase >3 x upper limit of normal; [†]Bleeding refers to previous bleeding history and/or predisposition to bleeding.

1. National Institute for Health and Care Excellence. NICE Guidance NG158. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. March 2020. Available at: https://www.nice.org.uk/guidance/ng158/. Last accessed: August 2020; 2 Camm AJ, et al. *Eur Heart J* 2010;31(19):2369–2429. 3. Brown JD, et al. *J Am Heart Assoc* 2018;7:e007901.

NICE recommendations for long-term anticoagulation for the prevention of recurrent VTE¹



Take into account the persons preferences, and their clinical situation when selecting an anticoagulant for long-term treatment. All prescribing must be in accordance with the appropriate SmPC

*Apixaban, rivaroxaban and edoxaban are not recommended in patients with a CrCl of <15 mL/min, and patients undergoing dialysis. Apixaban and rivaroxaban should also be used with caution in patients with severe renal impairment (CrCl 15–29 mL/min).^{2–4 †}Dabigatran is contraindicated in patients with a CrCl of <30mL/min.⁵ *The efficacy and safety outcomes of apixaban in the treatment of DVT / PE and prevention of recurrent DVT / PE in patients with active cancer have not been established.²

[§]The DOACs, including apixaban, should not be used in patients with a history of thrombosis who are diagnosed with antiphosphdipid syndrome.^{2–5}

•

 National Institute for Health and Care Excellence. NICE Guidance NG158. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. March 2020. Available at: https://www.nice.org.uk/guidance/ng158/. Last accessed: August 2020;
 Apixaban SmPC. Available at: http://www.medicines.org.uk;
 Rivaroxaban SmPC. Available at: http://www.medicines.org.uk;

Apiadan SmPC. Available at: http://www.medicines.org.uk; 5. Dabigatran SmPC. Available at: http://www.medicines.org.uk;

Design of DOAC trials for the prevention of recurrent VTE

Study drug	Trial	Patients (n)	Treatment before randomisation	Study drug dosing	Comparator	Treatment length (months)
Dabigatran	RE-MEDY ¹	2,866	3–12 months of approved anticoagulant or dabigatran	Dabigatran 150 mg BD	Warfarin INR 2.0–3.0	6–36
Rivaroxaban	EINSTEIN- CHOICE ²	3,365	6–12 months of anticoagulation, such as VKA or DOAC	Rivaroxaban 10 mg or 20 mg OD	Aspirin 100 mg	6–12
Dabigatran	RE-SONATE ¹	1,343	6–18 months of oral anticoagulant or dabigatran	Dabigatran 150 mg BD	Placebo	6 or 12
Rivaroxaban	EINSTEIN-EXT ³	1,197	6 or 12 months of VKA or rivaroxaban	Rivaroxaban 20 mg OD	Placebo	30
Apixaban	AMPLIFY-EXT ⁴	2,482	6–12 months of standard therapy or apixaban	Apixaban 2.5 mg or 5 mg BD*	Placebo	12

There are no head-to-head studies between these agents. There are limitations such as differing patient populations, designs and outcomes, and caution should therefore be exercised when interpreting the results. No conclusions about the relative efficacy of any of these agents should be drawn from the trial data. Please refer to the individual SmPCs for further information.

*Apixaban 5 mg BD is not a licensed dose for the prevention of VTE recurrence.⁵ Results shown for the apixaban arm will be for the licensed dose of apixaban 2.5 mg BD only.

BD: twice daily; INR: International Normalised Ratio; OD: once daily; VKA: vitamin K antagonist.

1. Schulman S, et al. *N Engl J Med* 2013;368:709–718; 2. Weitz JI, et al. *N Engl J Med* 2017;376:1211–1222; 3. EINSTEIN Investigators. *N Engl J Med* 2010;363:2499–2510; 4. Agnelli G, et al. *N Engl J Med* 2013;368:699–708; 5. Apixaban SmPC. Available at: http://www.medicines.org.uk. EINSTEIN-CHOICE: Rivaroxaban 20 mg OD and 10 mg OD reduced the risk of recurrent VTE compared with aspirin with no significant difference in the incidence of major bleeding

Rivaroxaban vs aspirin


The EINSTEIN-CHOICE trial was a double-blind, randomised trial comparing two doses of rivaroxaban (20 mg OD or 10 mg OD) with aspirin 100 mg OD for 6–12 months in patients with DVT or PE who had completed 6–12 months of anticoagulation therapy¹

	HR (95% CI)	<i>P</i> value						
Primary efficacy outcome*								
Recurrent VTE								
Rivaroxaban 20 mg (n=1,107)	0.34 (0.20–0.59)	<0.001	-					
Rivaroxaban 10 mg (n=1,127)	0.26 (0.14–0.47)	<0.001	-					
Safety outcomes [†]		•						
Major bleeding (primary safety								
outcome)								
Rivaroxaban 20 mg (n=1,107)	2.01 (0.50–8.04)	0.32						
Rivaroxaban 10 mg (n=1,127)	1.64 (0.39–6.84)	0.50						
Major or CRNM bleeding								
Rivaroxaban 20 mg (n=1,107)	1.59 (0.94–2.69)	0.08						
Rivaroxaban 10 mg (n=1,127)	1.16 (0.67–2.03)	0.60						
			0	2	4	6	8	10
		r	Favours ivaroxabar	ı	Fav	ours aspir	in	

*The primary efficacy outcome of recurrent VTE was a composite of symptomatic recurrent fatal or non-fatal VTE. Efficacy outcomes were assessed in all the patients who had undergone randomisation and received at least one dose of a study drug (ITT population). Efficacy and safety outcomes were an alysed with the use of a Cox proportional hazards model, stratified according to the index diagnosis (DVT or PE); [†]Safety outcomes were considered during the time from administration of the first dose of a study drug to 48 hours after the administration of the last dose. Bleeding episodes were defined according to the criteria of the International Soci ety on Thrombosis and Haemostasis. EINSTEIN-Extension: Rivaroxaban reduced the risk of VTE recurrence but had a significantly higher incidence of major or CRNM bleeding compared with placebo¹

Rivaroxaban vs placebo

The EINSTEIN-Extension trial was a placebo-controlled, double-blind, randomised trial comparing 6–12 months of rivaroxaban treatment (20 mg OD) with placebo in patients who had completed 6–12 months of anticoagulation therapy for VTE¹




*The primary efficacy analysis was performed on an ITT basis; [†]The safety analysis included all patients who received the assigned study drug.

AMPLIFY-EXT: Apixaban reduced the risk of recurrent VTE and all-cause death with no significant difference in the rate of major bleeding compared with placebo

Apixaban vs placebo

The AMPLIFY-EXT trial was a randomised, double-blind study comparing apixaban (2.5 mg and 5 mg BD*) with placebo in patients who had completed 6–12 months of anticoagulation therapy for VTE¹



*The recommended dose of a pixaban for recurrent DVT and PE is 2.5 mg BD.²

[†]Efficacy data are based on the ITT analysis, which included 2,482 patients of the 2,486 patients randomised,[‡]Safety analyses included data from patients during the time that they were receiving treatment (the time between administration of the first dose of a study drug and 48 hours after administration of the last dose). NS: not significant; RR: relative risk.

Selecting patients for long-term treatment

- Consider the following factors when selecting patients for long-term treatment:
 - Provoked/unprovoked VTE
 - If provoked VTE, is the provoking factor major or minor and transient or persistent?
 - First event or recurrence?
 - Thrombus site/burden
 - Bleeding risk during anticoagulation
 - Comorbidities
 - Patient preference

The decision of whether to **extend anticoagulation** beyond 3 months should be based on the **risk of recurrent VTE**, and should be balanced against the **risk of bleeding**, taking into account the **preferences of the patient**^{1,2}

DOAC dosing regimens across each stage of VTE treatment

Please refer to the individual DOAC SmPCs for full dosing recommendations


	Initial VTE treatment	Ongoing VTE Treatment	Prevention of Recurrent VTE					
Apixaban ¹	10 mg BD Day 1–7	5 mg BD Day 8 onwards for at least 3 months*	2.5 mg BD Following at least 6 months of oral anticoagulant therapy					
Apixaban, renal criteria ¹	Use with caution in severe renal impairment (CrCl 15–29 mL/min). Not recommended in CrCl <15 mL/min or in patients undergoing dialysis							
Dabigatran ²	Parenteral anticoagulant For at least 5 days (not to be taken concomitantly with dabigatran)	A dose reduction to 110mg BD is recommended in patients receiving concomitant verapamil or aged ≥80 years.						
Dabigatran, renal criteria ²	Consider a dose reduction to 110 mg BD based on individual assessment of bleeding and thromboembolic risk if CrCl 30 -50 mL/min. Contraindicated in CrCl <30 mL/min.							
Rivaroxaban ³	15 mg BD with food Day 1–21	20 mg OD with food Day 22 onwards for at least 3 months*	10 mg OD Following at least 6 months of oral anticoagulant therapy Consider 20 mg OD with food in patients in whom risk of recurrent VTE is considered high or who have developed recurrent VTE on 10 mg OD					
Rivaroxaban, renal criteria ³								
Edoxaban ⁴	Parenteral anticoagulant For at least 5 days (not to be taken concomitantly with edoxaban)60 mg OD For at least 3 months* A dose adjustment to 30 mg OD is required in patients with CrCl 15–50 mL/min, or body weight ≤60 kg, or concomitant use with ciclosporin, dronedarone, erythromycin or ketoconazole							
Edoxaban, renal criteria ⁴								
	he duration of overall therapy should be individualised after careful assessment of the treatment benefit against the risk of bleeding. Short duration of treatment (at least 3 months) should be based on transient risk factors (e.g. recent surgery, trauma, immobilisation).							

⁺Daily dose of dabigatran of 300 mg or 220 mg should be selected based on an individual assessment of the thromboembolic risk and the risk of bleeding.

Consider the implications of secondary complications

PTS: A complication of DVT

- Caused by damage to venous valves by thrombus in acute DVT¹
- Annual incidence is 1/1,000 PY, and 20–50% of patients develop PTS as a long-term sequela¹
- Anticoagulation is required to prevent thrombus formation¹
- Risk factors include old age and impaired venous circulation²



CTEPH: chronic thromboembolic pulmonary hypertension; PTS: post-thrombotic syndrome; PY: person years.

Summary of NICE recommendations for oral anticoagulation for confirmed VTE¹

Acute treatment¹

When offering anticoagulation, take into account comorbidities, contraindications and the person's preferences

For patients **who do not have** CrCl <15mL/min, active cancer, triple positive APS, extreme body weight <50kg or >120kg, or a PE without haemodynamic instability :^{*†‡§}

Offer either apixaban or rivaroxaban to people with a confirmed proximal DVT or PE

If neither apixaban nor rivaroxaban is suitable offer one of the following:

- LMWH for ≥5 days followed by dabigatran
- LMWH for ≥5 days followed by edoxaban
- LMWH concurrently with a VKA for ≥5 days or until the INR is ≥2.0 in 2 consecutive readings, followed by a VKA on its own

Offer anticoagulation treatment for \geq 3 months for people with confirmed proximal DVT or PE

Long-term treatment (beyond 3 months) in appropriate patients¹

For people who do not have CrCl <15mL/min, active cancer, established triple positive APS, extreme body weight <50kg or >120kg, or a PE with haemodynamic instability:^{*†‡}

- Offer continued treatment with current anticoagulant if it is well tolerated
- If the current treatment is not well tolerated or clinical situation or person's preferences have changed, consider switching to apixaban if current treatment is a DOAC other than apixaban

When prevention of recurrent DVT and PE is indicated, the 2.5 mg BD dose of apixaban should be initiated following completion of 6 months of treatment with apixaban 5 mg twice daily or with another anticoagulant

See the guidelines for further details. All prescribing must be in accordance with the appropriate SmPC.

*The efficacy and safety outcomes of apixaban in the treatment of DVT/PE and prevention of recurrent DVT/PE in patients with active cancer have not been established.²

[†]The DOACs, including apixaban, should not be used in patients with a history of thrombosis who are diagnosed with antiphospho lipid syndrome.^{2–5} [‡]Apixaban, rivaroxaban and edoxaban are not recommended in patients with a CrCl of <15 mL/min and patients undergoing dialysis, and should also be used with caution in patients with severe renal impairment (CrCl 15–29 mL/min). Dabigatran is contraindicated in patients with a CrCl of <30 mL/min.^{2–5}

§See the NICE NG158 guidelines for recommendations in these patient groups

 National Institute for Health and Care Excellence. NICE Guidance NG158. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. March 2020. Available at: https://www.nice.org.uk/guidance/ng158/. Last accessed: August 2020;
 Apixaban SmPC. Available at: http://www.medicines.org.uk;
 Bivaroxaban SmPC. Available at: http://www.medicines.org.uk;
 Dabigatran SmPC. Available at: http://www.medicines.org.uk;
 Edoxaban SmPC. Available at: http://www.medicines.org.uk;

Patient case study

Patient: Antonio*



Patient history

- Provoked DVT 5 years ago following a hip replacement
- Gastrointestinal bleeding from gastric ulcers (17 months previously) successfully treated
- Works as a computer programmer and has a sedentary lifestyle
- Mild symptomatic heart failure (LVEF = 42%)

Patient information Medications 61 Age Enalapril 10 mg BD 96.2 kg/ Presentation Weight/BMI 32.4 kg/m² • Visited his GP with pain and swelling in his left leg and calf; back of calf was red with pitting oedema 149/97 Blood pressure • Had experienced worsening pain in his left leg for almost 2 weeks mmHg following a long-haul flight (8 hours) and a 2-hour wait for his CrCl (Cockcroft-62 mL/min luggage Gault)

*Patient is fictitious.


GP: general practitioner; LVEF: left ventricular ejection fraction.

Questions for discussion (1)

Q What risk factors does Antonio have for a VTE?

Q What risk factors does Antonio have for a VTE?

A Antonio has the following risk VTE factors:



*Heart disease, metabolic, endocrine or respiratory pathologies, acute infectious diseases and inflammatory conditions.

 NICE clinical guideline (CG92). Venous thromboembolism: reducing the risk for patients in hospital. January 2010. Available at: https://www.nice.org.uk/guidance/cg92/resources. Last accessed: August 2020; 2. Bahl V, et al. Ann Surg 2009;251:344–350.

Questions for discussion (2)

After conducting a physical exam, Antonio scored 3 on the two-level Wells DVT risk score



Should he be referred for a ultrasound scan?

Questions for discussion (2)

After conducting a physical exam, Antonio scored 3 on the two-level Wells DVT risk score

Q Should he be referred for a ultrasound scan?

Yes, Antonio should be referred for an ultrasound scan if DVT is likely after conducting a physical examination and the two-level Wells score test

1. National Institute for Health and Care Excellence. NICE Guidance NG158. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. March 2020. Available at: https://www.nice.org.uk/guidance/ng158/. Last accessed: August 2020.

Questions for discussion (3)

Antonio was prescribed 3 months treatment with apixaban and has his follow-up review in general practice



When deciding the length of treatment, what risk factors need to be considered?

Questions for discussion (3)


Antonio was prescribed 3 months treatment with apixaban and has his follow up review in general practice

Q	When deciding the length of treatment, what risk factors need to be considered?
А	 The following risk factors should be considered for long term treatment:¹ Unprovoked VTE
	 Provoked VTE with minor transient or persistent provoking factor Recurrent VTE Thrombus site/burden No additional risk of major bleeding Medical comorbidities

The decision of whether to **extend anticoagulation** beyond 3 months should be based on the **risk of recurrent VTE**, and should be balanced against the **risk of bleeding**, taking into account the **preferences of the patient**^{1,2}

Selecting patients for long-term treatment – it is important to have decision pathways in place

A review should take place between **3 and 6 months post-diagnosis** to decide on the need for long-term anticoagulation for the prevention of recurrent VTE. This review should be **scheduled at the time of discharge**¹



Adapted from BMS-Pfizer Expert and Anticoagulation UK Working Group Meeting. 2018¹

In most cases, the decisions should be made by secondary care specialists or those in settings such as a dedicated VTE centre¹

 BMS-Pfizer Expert and Anticoagulation UK Working Group Meeting. Developing Optimal Standards of Care for the Prevention of Recurrent Venous Thromboembolism (VTE): Consensus Statement. Available at: http://www.anticoagulationuk.org/news/2019-01-11-developing-optimal-standards-of-care-for-the-prevention-ofrecurrent-venous-thromboembolism-vte-consensus-statement. Last accessed August 2020.

Summary

- The incidence of VTE is approximately one per 1,000 people annually¹ with an estimated 30-day mortality risk of 3% for DVT and 31% for PE²
 - Effective treatment is therefore important
- The two-level Wells risk score aids in VTE diagnosis, which may also require USS, chest X-ray or D-dimer testing³
- Primary care health professionals have an important role in identifying potential cases of VTE, ensuring that prompt anticoagulation treatment is given when indicated, and supporting patients during anticoagulation treatment⁴
- Long-term treatment should be considered in appropriate patients, and may reduce the risk of recurrence and secondary complications^{5–9}

 Stone J, et al. Cardiovasc Design Ther 2017;9(Suppl. 3):S276–S284; 2. Søgaard S, et al. Circulation 2014;130:829–836; 3. National Institute for Health and Care Excellence. NICE Guidance NG158. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. March 2020. Available at: https://www.nice.org.uk/guidance/ng158/. Last accessed: August 2020; 4. Patel R. Int J Gen Med 2016;9:107-115; 5. Agnelli G, et al. N Engl J Med 2013;368:699–708; 6. Schulman S, et al. N Engl J Med 2013;368:709–718; 7. EINSTEIN Investigators. N Engl J Med 2010;363:2499–2510; 8. Weitz JI, et al. N Engl J Med 2017;376:1211–1222; 9. Apixaban SmPC. Available at: http://www.medicines.org.uk.